"Similar mutations that cause resistance have been observed in laboratory studies, but so far no such cases have been reported in patients treated with the remedial injection drug," said one researcher, according to Bloomberg.
The patient, a 70-year-old woman being treated for a condition called "non-Hodgkin's lymphoma", developed coronary heart disease in May. Remedicivir helped him reduce his symptoms, but he could not completely clear the infection, which affected his sense of smell.
Genetic analysis of this coronavirus showed that a mutation was made during treatment, which seems to have reduced the effectiveness of RemedSivir!
The researchers said that this highlights the importance of monitoring resistance to RamedSavier in immunocompromised patients.
